Archive

IBD: the perfect example of translational medicine?

The genetic and clinical heterogeneity of IBD means translational research has a key role to play. A session dedicated to translational and basic science at UEG Week 2019… read more.

IBD healthcare and patient-reported outcomes

An oral abstract session dedicated to patient-reported outcomes (PROs) in IBD included surveys from France and the Netherlands and from the multi-centre ICONIC study.. Written by Maria Dalby

Disease monitoring in IBD – implementation in practice

Dr Maria Abreu (Miami, USA) gives us an overview of implementing disease monitoring and its challenges in clinical practice  Written by Maria Dalby

Late-breaking abstracts: IBD highlights

A subcutaneous formulation of infliximab, known as CT-P13 SC, has been developed with a view to offer greater flexibility and convenience for patients. 

Randomised controlled trials session

In a round-up of randomised controlled studies in IBD at UEG Week 2019 included results from the maintenance phase of the UNIFI study in UC and a phase-3… read more.

Updates from VARSITY: histologic remission

Professor Jean-Frédéric Colombel (Icahn School of Medicine at Mount Sinai, New York, USA) opened the symposium with an overview of how treatment targets in UC have evolved from improving… read more.

Highlights from UEGW 2019

UEGW 2019, held in Barcelona, Spain, was a very interesting meeting, covering a wide range of hot topics from the world on IBD. The meeting was well-attended with… read more.

UEGW 2018: Clinical trials in IBD – late-breaking abstracts

Among the late-breaking clinical trial abstracts at UEG Week were new data for ustekinumab in UC, a new formulation for subcutaneous administration of vedolizumab, and early clinical data… read more.

UEGW 2018: Future therapies in IBD

Professor Stefan Schreiber (Germany) discusses  the future of therapies in IBD.

UEGW 2018: Debate: Treat to target and tight monitoring in IBD

Dr Filip Baert (Belgium) discusses the debate at UEGW on treating to target and tight monitoring in IBD.

UEGW 2018: IBD: from epidemiology to costs and outcome

Dr Johan Burisch (Denmark) reviews data he presented on the cost saving effect of biological therapy in patients with IBD.

UEGW 2015: Vaccination in IBD. An interview with Dr Herbert Tilg, Innsbruck Medical University, Austria. Conducted by Sanjay Tanday